Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316186 · ClinicalTrials.gov registry record · Phase 2
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
A Phase 2 study of Lung Cancer, Small Cell, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 13
- Study locations
NCT00316186 is a Phase 2 study of Lung Cancer, Small Cell that has completed, run by GlaxoSmithKline. The registered enrollment target is 33 participants. The trial reports 13 study locations across 11 states.
The verdict
NCT00316186, a Phase 2 study of Lung Cancer, Small Cell, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG topotecan
Study Locations (13)
California
- GSK Investigational Site - Concord
- GSK Investigational Site - Sacramento
Florida
- GSK Investigational Site - Boca Raton
- GSK Investigational Site - Hollywood
Arizona
- GSK Investigational Site - Tucson
Illinois
- GSK Investigational Site - Chicago
Indiana
- GSK Investigational Site - Munster
Louisiana
- GSK Investigational Site - Metairie
Missouri
- GSK Investigational Site - St Louis
New York
- GSK Investigational Site - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00316186
The ClinicalTrials.gov registry entry for NCT00316186 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer, Small Cell appearing as the primary indexed condition, and to 2 interventions - of which carboplatin is the first listed.
NCT00316186 reports 13 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00316186 about?
NCT00316186 is a clinical study titled "First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin". This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.
What is the current status of trial NCT00316186?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2005-06. Estimated completion is 2009-05.
What conditions does trial NCT00316186 study?
This clinical trial studies the following conditions: Lung Cancer, Small Cell.
What interventions are being tested in trial NCT00316186?
The interventions under investigation include: carboplatin (DRUG), topotecan (DRUG).
Who is sponsoring clinical trial NCT00316186?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00316186 being conducted?
This trial has 13 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer, Small Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.